| DC8112 |
Pirarubicin(THP)
Featured
|
Pirarubicin is an analogue of the anthracycline anti-neoplastic doxorubicin, which is an inhibitor of Topo II. |
|
| DC8792 |
Pirfenidone(AMR69)
Featured
|
Pirfenidone(AMR69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3. |
|
| DCAPI1575 |
Pirlimycin |
Pirlimycin |
|
| DC12558 |
Pirlindole Mesylate |
Pirlindole is a novel potent inhibitor of Enteroviruse that targets Viral Protein 2C, inhibits EV-B and EV-D through the inhibition of genome replication (CV-B3 EC50=9.91 uM). . |
|
| DC10364 |
(±)-Pirmenol
Featured
|
Pirmenol inhibits IK.ACh by blocking muscarinic receptors. The IC50 of Pirmenol for inhibition of Carbachol-induced IK.ACh is 0.1 μM. |
|
| DC7155 |
Pirodavir (R 77975)
Featured
|
Pirodavir (R 77975) is the prototype of a novel class of broad-spectrum antipicornavirus compounds; potent human rhinovirus (HRV) capsid-binding inhibitor. |
|
| DC20506 |
PIT-1 |
PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain binding with IC50 of 30 uM, Kd of 43.2 uM. |
|
| DCAPI1385 |
Ropinirole HCl |
Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis. |
|
| DCAPI1470 |
Pitavastatin Calcium
Featured
|
Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis. Alternate studies show that pitavastatin can suppress oxygen production in endothelial cells by inhibiting NADPH o |
|
| DC9357 |
Pivmecillinam (hydrochloride) |
Pivmecillinam(Amdinocillin pivoxil) is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic. |
|
| DCAPI1216 |
Pizotifen malate |
Pizotifen malate |
|
| DC21940 |
Pizuglanstat
Featured
|
Pizuglanstat is a potent, selective prostaglandin D synthase inhibitor.. |
|
| DC21512 |
PJ-68 |
PJ-68 is a potent, selective inhibitor of arginine methyltransferase PRMT5 with IC50 of 517 nM, shows no inhibitory activity against type I PRMT family members ( (PRMT1, 3, 4, 6, and 8). |
|
| DC22109 |
PK4C9 |
PK4C9 (Homocarbonyltopsentin) is a small-molecule stem-loop RNA structure TSL2-binding compound (EC50=16.1 uM) that increases SMN2 exon 7 (E7) splicing and rescues downstream molecular alterations in SMA cells. |
|
| DC23280 |
PK-7088 |
PK-7088 is a small molecule mutant p53 Y220C reactivator, promotes correct folding of Y220 mutant p53 and induces expression of p53 targets p21 and the Noxa, triggers nuclear export of the pro-apoptotic Bax protein to mitochondria.. |
|
| DC23146 |
PKC beta II inhibitor H6 |
PKC-IN-1 is a poent PKC beta II inhibitor with Ki of 14.9 nM, extracted from patent WO 2008096260 A1 as compound example H6.. |
|
| DC23835 |
PKC-IN-7 |
PKC-IN-7 is a potent, selective, reversible, ATP-competitive PKCα/β inhibitor with IC50 of 4.7/3.3 nM. |
|
| DC10821 |
PKG drug G1
Featured
|
PKG drug G1 has been shown to induce the oxidative activation of protein kinase G Iα, which in vivo results in dilation of blood vessel and blood pressure lowering; an antihypertensive. |
|
| DC12504 |
PL265 |
PL265 (PL-265) is a dual enkephalinase inhibitor, alleviate corneal pain and inflammation in vivo.. |
|
| DC12462 |
PLB-1001
Featured
|
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1]. |
|
| DC20012 |
Plecanatide acetate
Featured
|
Plecanatide acetate is a guanylate cyclase-C (GC-C) receptor agonist, binds and activates GC-C receptor, with an EC50 of 190 nM in T84 cells. Plecanatide acetate shows an-inflammatory activity in models of murine colitis. |
|
| DC8749 |
Plinabulin
Featured
|
Plinabulin (NPI-2358) is a vascular disrupting agents (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. |
|
| DC23333 |
PLK1-IN-14f |
PLK1-IN-14f is a potent PLK1 inhibitor, exhibits potent activity against a panel cancer cell lines with GI50 values ranging from 0.30 to 0.60 uM. |
|
| DC7239 |
PluriSln 1(NSC 14613)
Featured
|
PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs. |
|
| DC21518 |
PLX5622
Featured
|
PLX5622 is a a potent, selective, orally active inhibitor of CSF1R tyrosine kinase (c-Fms) activity with Ki of 5.9 nM, 60-fold less potency against KIT. |
|
| DC8107 |
PLX647
Featured
|
PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively. |
|
| DC22199 |
PM-43I |
PM-43I is a selective inhibitor of STAT5/6 Src Homology 2 (SH2) domain, binds recombinant STAT6 and STAT5B (IC50=1.8 and 3.8 uM) with much lower affinity for STAT3 (IC50=29.9 uM). |
|
| DC22200 |
PMX-53
Featured
|
PMX53 (Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg)) is a potent C5a receptor (CD88) antagonist with IC50 of 20 nM, also is an agonist for Mas-related gene 2 (MrgX2) in human mast cells; PMX-53 (10 nM) inhibited C5a-induced Ca(2+) mobilization in HMC-1 cells, but at higher concentrations (>30 nM) it caused degranulation in LAD2 mast cells, CD34(+) cell-derived mast cells, and RBL-2H3 cells stably expressing MrgX2; inhibits zymosan-, carrageenan-, LPS- and antigen-induced hypernociception in rats. |
|
| DC20508 |
PNPLA4-IN-1 |
PNPLA4-IN-1 is a potent, selective, and irreversible PNPLA4 inhibitor with IC50 of 1.8 uM (separated membrane proteome fraction), shows in-cell inhibition of PNPLA4 with IC50 of 11.7 uM.. |
|
| DC20509 |
PNR-7-02 |
PNR-7-02 is a specific inhibitor of human DNA Polymerase η (hPol η) with IC50 of 8 uM, exhibits 5-10-fold specificity for hPol η over other replicative Pols. |
|
